Free tool
FAERS Monitor: Aleve
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020204 or its brand name (Aleve, Naproxen Sodium). Reports on generic versions are filed under their own applications.
Reports
67,356
Serious
27,436
41% of reports
Hospitalization
12,276
Death reported
5,059
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective11,391
- fatigue5,094
- product use issue4,817
- pain4,764
- nausea4,287
- arthralgia4,100
- headache4,070
- off label use4,008
- dizziness3,972
- diarrhoea3,952
- rash3,569
- vomiting3,471
- drug hypersensitivity3,330
- abdominal discomfort3,180
- abdominal pain upper3,159
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 644 |
| 2005 | 773 |
| 2006 | 633 |
| 2007 | 659 |
| 2008 | 3,280 |
| 2009 | 1,851 |
| 2010 | 786 |
| 2011 | 1,013 |
| 2012 | 1,808 |
| 2013 | 1,672 |
| 2014 | 3,782 |
| 2015 | 7,074 |
| 2016 | 6,846 |
| 2017 | 5,779 |
| 2018 | 4,953 |
| 2019 | 4,818 |
| 2020 | 3,673 |
| 2021 | 3,063 |
| 2022 | 2,961 |
| 2023 | 2,839 |
| 2024 | 3,552 |
| 2025 | 3,270 |
| 2026 | 1,625 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,986,803 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product use issueSignal | 4,817 | 8.2 | 8.0 | 29,876 |
| abdominal discomfortSignal | 3,180 | 6.0 | 5.8 | 13,143 |
| drug hypersensitivitySignal | 3,330 | 5.4 | 5.3 | 11,997 |
| abdominal pain upperSignal | 3,159 | 4.9 | 4.7 | 9,597 |
| arthralgiaSignal | 4,100 | 3.1 | 3.0 | 5,889 |
| drug ineffectiveSignal | 11,391 | 2.7 | 2.7 | 13,037 |
| rashSignal | 3,569 | 2.6 | 2.5 | 3,464 |
| dizzinessSignal | 3,972 | 2.5 | 2.4 | 3,626 |
| painSignal | 4,764 | 2.4 | 2.4 | 4,108 |
| vomitingSignal | 3,471 | 2.3 | 2.2 | 2,631 |
| fatigueSignal | 5,094 | 2.0 | 2.0 | 2,825 |
| headacheSignal | 4,070 | 2.0 | 2.0 | 2,189 |
| diarrhoea | 3,952 | 1.9 | 1.9 | 1,778 |
| nausea | 4,287 | 1.7 | 1.6 | 1,262 |
| off label use | 4,008 | 1.4 | 1.4 | 541 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.